Paper33266366
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y and 1 other. Int J Mol Sci, 2020. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Papers, record 33266366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33266366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Histone Deacetylase Inhibitors | Major topic |
| Histone Deacetylases | Major topic |
| Animals | |
| Humans | |
| Protein Conformation |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 91953102 | National Natural Science Foundation of China | PubMed | ||
| 2019A1515011265 | Guangdong Nature Science Foundation | PubMed | ||
| 19ykzd26 | Fundamental Research Funds for the Sun Yat-sen Universities | PubMed | ||
| 2019QN01Y299 | the Pearl River Talent Recruitment Program | PubMed |
Source PubMed
References164
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26831668 | Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. | Tumour Biol | 2016 | https://conductscience.org/library/papers/26831668 | PubMed |
| 2 | 30544838 | Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30544838 | PubMed |
| 3 | 28192979 | Structural Characterization of Native Proteins and Protein Complexes by Electron Ionization Dissociation-Mass Spectrometry. | Anal Chem | 2017 | https://conductscience.org/library/papers/28192979 | PubMed |
| 4 | 21723733 | Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. | Bioorg Med Chem | 2011 | https://conductscience.org/library/papers/21723733 | PubMed |
| 5 | 24900743 | Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. | ACS Med Chem Lett | 2013 | https://conductscience.org/library/papers/24900743 | PubMed |
| 6 | 25131830 | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/25131830 | PubMed |
| 7 | 22116549 | Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. | Leukemia | 2012 | https://conductscience.org/library/papers/22116549 | PubMed |
| 8 | 29302039 | Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. | Nat Commun | 2018 | https://conductscience.org/library/papers/29302039 | PubMed |
| 9 | 32682428 | The application of histone deacetylases inhibitors in glioblastoma. | J Exp Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32682428 | PubMed |
| 10 | 28139258 | Targeting Class I Histone Deacetylases in a "Complex" Environment. | Trends Pharmacol Sci | 2017 | https://conductscience.org/library/papers/28139258 | PubMed |
| 11 | 21049000 | Physiological roles of class I HDAC complex and histone demethylase. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/21049000 | PubMed |
| 12 | 20197387 | SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. | Mol Cancer Ther | 2010 | https://conductscience.org/library/papers/20197387 | PubMed |
| 13 | 32509730 | Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents. | Front Chem | 2020 | https://conductscience.org/library/papers/32509730 | PubMed |
| 14 | 24403121 | Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. | ChemMedChem | 2014 | https://conductscience.org/library/papers/24403121 | PubMed |
| 15 | 15565322 | Sin3: a flexible regulator of global gene expression and genome stability. | Curr Genet | 2005 | https://conductscience.org/library/papers/15565322 | PubMed |
| 16 | 27377864 | Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. | Bioorg Med Chem | 2016 | https://conductscience.org/library/papers/27377864 | PubMed |
| 17 | 9501205 | A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9501205 | PubMed |
| 18 | 32585896 | Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32585896 | PubMed |
| 19 | 27556043 | HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. | Biomed Res Int | 2016 | https://conductscience.org/library/papers/27556043 | PubMed |
| 20 | 25695609 | Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. | Cell Death Dis | 2015 | https://conductscience.org/library/papers/25695609 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42871557 | HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42871557 | PubMed |
| 42669843 | Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines. | Brain Pathol | 2026 | https://conductscience.org/library/papers/42669843 | PubMed |
| 42653320 | Epigenetic Control of Stress-Induced Depression: Emerging Roles of HDAC3 and HDAC6. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653320 | PubMed |
| 42444693 | 2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity. | RSC Adv | 2026 | https://conductscience.org/library/papers/42444693 | PubMed |
| 42401937 | Acetylation in ovarian cancer: mechanistic insights into drug resistance and emerging therapeutic opportunities. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/42401937 | PubMed |
| 42101139 | Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery. | Med Res Rev | 2026 | https://conductscience.org/library/papers/42101139 | PubMed |
| 41939854 | HDACs targeting from traditional Chinese medicine: mechanisms and therapeutic potential in rheumatoid arthritis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41939854 | PubMed |
| 41890122 | Multicomplex Integrative Structural Modeling of a Human Histone Deacetylase Interactome. | bioRxiv | 2026 | https://conductscience.org/library/papers/41890122 | PubMed |
| 41335282 | Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335282 | PubMed |
| 41219568 | Exploration of 2-Mercaptoquinazolin-4(3H)-one Based N-Hydroxyheptanamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Anticancer Bioevaluation. | Pharm Res | 2025 | https://conductscience.org/library/papers/41219568 | PubMed |
| 40284012 | Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40284012 | PubMed |
| 40263937 | Histone deacetylases and their inhibitors in kidney diseases. | Mol Ther | 2025 | https://conductscience.org/library/papers/40263937 | PubMed |
| 40187727 | Senkyunolide A interrupts TRAF6-HDAC3 interaction to epigenetically suppress c-MYC and attenuate cholestatic liver injury. | J Adv Res | 2026 | https://conductscience.org/library/papers/40187727 | PubMed |
| 39939814 | Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051. | Commun Biol | 2025 | https://conductscience.org/library/papers/39939814 | PubMed |
| 39807197 | Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article. | RSC Adv | 2025 | https://conductscience.org/library/papers/39807197 | PubMed |
| 39174535 | Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39174535 | PubMed |
| 39069707 | A Comprehensive Review on Novel Pathways in Cancer Treatment: Clinical Applications and Future Prospects. | Curr Cancer Drug Targets | 2025 | https://conductscience.org/library/papers/39069707 | PubMed |
| 38822399 | Advances in targeting histone deacetylase for treatment of solid tumors. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38822399 | PubMed |
| 38375511 | Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies. | 3 Biotech | 2024 | https://conductscience.org/library/papers/38375511 | PubMed |
| 37854628 | Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition. | ACS Pharmacol Transl Sci | 2023 | https://conductscience.org/library/papers/37854628 | PubMed |
Genes37
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33266366
GET https://conductscience.org/api/papers/v1/33266366/references?page=2